title: A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.
abstract: BACKGROUND
  The purpose of this study was to determine in limited small-cell lung cancer if locoregional irradiation concurrently with induction chemotherapy with cisplatin and etoposide prolongs survival when cisplatin is given daily as a radiosensitiser.
  
  
  METHODS
  Two-hundred and four eligible patients were randomised between standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m(2) day 1) plus etoposide and daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m(2)/day) plus etoposide. Chemotherapy and chest irradiation (39.90 Gy in 15 fractions >3 weeks) both started on day 1.
  
  
  RESULTS
  There was no difference in survival between both arms with respective median, 2 and 5 years of 15.5 months, 35% and 18% in arm A and 17.0 months, 38% and 21% in arm B (P = 0.50). Performance status and T status were identified as independent prognostic factors for survival. In terms of local control rate, there was a statistical trend in favour of arm A with 2% only local relapse versus 10% in arm B. Daily cisplatin radiosensitisation was associated with more oesophagitis and thrombopenia but less nephrotoxicity.
  
  
  CONCLUSIONS
  Induction chemoradiotherapy resulted in both arms in good long-term survival, comparable to the best reported results and without improvement by daily cisplatin administration.
authors.affiliation: Institut Jules Bordet, Brussels, Belgium. sculier@bordet.be
authors.forename: J P
authors.initials: JP
authors.lastname: Sculier
authors.forename: J J
authors.initials: JJ
authors.lastname: Lafitte
authors.forename: A
authors.initials: A
authors.lastname: Efremidis
authors.forename: M C
authors.initials: MC
authors.lastname: Florin
authors.forename: J
authors.initials: J
authors.lastname: Lecomte
authors.forename: M C
authors.initials: MC
authors.lastname: Berchier
authors.forename: M
authors.initials: M
authors.lastname: Richez
authors.forename: T
authors.initials: T
authors.lastname: Berghmans
authors.forename: A
authors.initials: A
authors.lastname: Scherpereel
authors.forename: A P
authors.initials: AP
authors.lastname: Meert
authors.forename: G
authors.initials: G
authors.lastname: Koumakis
authors.forename: N
authors.initials: N
authors.lastname: Leclercq
authors.forename: M
authors.initials: M
authors.lastname: Paesmans
authors.forename: P
authors.initials: P
authors.lastname: Van Houtte
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D011838:Radiation-Sensitizing Agents; D005047:Etoposide; D002945:Cisplatin